Skip to main content
SpringerLink
Log in

Reply to Passamonti et al: ruxolitinib and survival improvement in patients with myelofibrosis

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Barosi G, Tefferi A, Besses C, Birgegard G, Cervantes F, Finazzi G et al. Clinical endpoints for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). Leukemia, e-pub ahead of print 25 August 2014; doi:10.1038/leu.2014.250.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for the Study of Myelofibrosis, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy

    G Barosi

  2. Division of Experimental Medicine, Department of Medicine, Haematology Research Centre, Imperial College London, London, UK

    R P Gale

Authors
  1. G Barosi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R P Gale
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R P Gale.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barosi, G., Gale, R. Reply to Passamonti et al: ruxolitinib and survival improvement in patients with myelofibrosis. Leukemia 29, 740 (2015). https://doi.org/10.1038/leu.2014.312

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2014.312

  • Springer Nature Limited

Search

Navigation